Field J - Search Results

1

Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.

Nathan DG, Field J, Lin G, Neuberg D, Majerus E, Onyekwere O, Keefer J, Okam M, Ross A, Linden J. Nathan DG, et al. Among authors: field j. Trans Am Clin Climatol Assoc. 2012;123:312-7; discussion 317-8. Trans Am Clin Climatol Assoc. 2012. PMID: 23303999 Free PMC article. Clinical Trial.

2

NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.

Wallace KL, Marshall MA, Ramos SI, Lannigan JA, Field JJ, Strieter RM, Linden J. Wallace KL, et al. Among authors: field jj. Blood. 2009 Jul 16;114(3):667-76. doi: 10.1182/blood-2009-02-205492. Epub 2009 May 11. Blood. 2009. PMID: 19433855 Free PMC article.

3

P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease.

Polanowska-Grabowska R, Wallace K, Field JJ, Chen L, Marshall MA, Figler R, Gear AR, Linden J. Polanowska-Grabowska R, et al. Among authors: field jj. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2392-9. doi: 10.1161/ATVBAHA.110.211615. Epub 2010 Nov 11. Arterioscler Thromb Vasc Biol. 2010. PMID: 21071696 Free PMC article.

4

Targeting iNKT cells for the treatment of sickle cell disease.

Field JJ, Nathan DG, Linden J. Field JJ, et al. Clin Immunol. 2011 Aug;140(2):177-83. doi: 10.1016/j.clim.2011.03.002. Epub 2011 Mar 22. Clin Immunol. 2011. PMID: 21429807 Free PMC article. Review.

5

The role of fibrocytes in sickle cell lung disease.

Field JJ, Burdick MD, DeBaun MR, Strieter BA, Liu L, Mehrad B, Rose CE Jr, Linden J, Strieter RM. Field JJ, et al. PLoS One. 2012;7(3):e33702. doi: 10.1371/journal.pone.0033702. Epub 2012 Mar 19. PLoS One. 2012. PMID: 22442712 Free PMC article. Clinical Trial.

6

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.

Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, Linden J, Nathan DG. Field JJ, et al. Blood. 2013 Apr 25;121(17):3329-34. doi: 10.1182/blood-2012-11-465963. Epub 2013 Feb 1. Blood. 2013. PMID: 23377438 Free PMC article. Clinical Trial.

7

NF-κB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors.

Lin G, Field JJ, Yu JC, Ken R, Neuberg D, Nathan DG, Linden J. Lin G, et al. Among authors: field jj. PLoS One. 2013 Oct 4;8(10):e74664. doi: 10.1371/journal.pone.0074664. eCollection 2013. PLoS One. 2013. PMID: 24124453 Free PMC article.

8

The role of adenosine signaling in sickle cell therapeutics.

Field JJ, Nathan DG, Linden J. Field JJ, et al. Hematol Oncol Clin North Am. 2014 Apr;28(2):287-99. doi: 10.1016/j.hoc.2013.11.003. Epub 2014 Jan 18. Hematol Oncol Clin North Am. 2014. PMID: 24589267 Free PMC article. Review.

9

Advances in sickle cell therapies in the hydroxyurea era.

Field JJ, Nathan DG. Field JJ, et al. Mol Med. 2014 Dec 16;20 Suppl 1(Suppl 1):S37-42. doi: 10.2119/molmed.2014.00187. Mol Med. 2014. PMID: 25549232 Free PMC article. Review.

10

NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease.

Field JJ, Majerus E, Ataga KI, Vichinsky EP, Schaub R, Mashal R, Nathan DG. Field JJ, et al. PLoS One. 2017 Feb 2;12(2):e0171067. doi: 10.1371/journal.pone.0171067. eCollection 2017. PLoS One. 2017. PMID: 28152086 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,189 results

Search Page